Asad Gul Rao

Dr. Asad Gul Rao


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 July 2025 in Endocrinology, Diabetes & Metabolism
Verified
Journal Article
Open access
ARAsad Gul Rao
Asad Gul Rao
SSSufyan Shahid
Sufyan Shahid
NPNeha Pervez
Neha Pervez
RPRamsha Pervez
Ramsha Pervez
RARaheel Ahmed
Raheel Ahmed
Background: Diabetes mellitus (DM) increases susceptibility to infection and worsens outcomes in sepsis, a leading cause of preventable death. However, population‐level trends in sepsis‐related mortality among diabetic individuals in the United States (US) remain poorly characterised, especially in the context of the COVID‐19 pandemic. This study evaluates national patterns, temporal shifts, and demographic disparities in sepsis‐related mortality in diabetic patients from 1999 to 2023. Methods: We conducted a retrospective analysis using the Centers for Disease Control and Prevention Wide‐ranging Online Data for Epidemiologic Research (CDC WONDER) Multiple Cause of Death database. Sepsis‐related deaths with co‐listed DM were extracted for US adults between 1999 and 2023. Age‐adjusted mortality rates (AAMRs) were calculated and Joinpoint regression was used to estimate annual percentage changes (APCs) and identify significant trends. Results: A total of 483,207 sepsis‐related deaths occurred in individuals with DM during the study period. AAMRs declined significantly from 1999 to 2018 (APC: −1.22; p < 0.001), reversed sharply from 2018 to 2021 (APC: +18.14; p = 0.01), and declined again through 2023 (APC: −12.25; p < 0.001). Mortality was highest among older adults (AAMR: 32.63), males (9.72 vs. 7.80 in females), and non‐Hispanic Black and American Indian/Alaska Native populations (AAMRs: 17.94 and 17.92, respectively). Hispanic populations showed the steepest pandemic‐era increase (APC: +22.49) and subsequent decline (APC: −20.43). Rural areas consistently had higher AAMRs than urban areas (8.77 vs. 8.27), with sharper increases during the pandemic. State‐level disparities widened dramatically from 2021 to 2023, and regionally, the South and Midwest exhibited the highest and most persistent mortality burdens. Conclusion: Sepsis‐related mortality in diabetic individuals in the US has undergone dynamic shifts over the past 25 years, punctuated by COVID‐19 era surges and shaped by deep‐rooted demographic, geographic, and structural inequities. These findings warrant integrated diabetes‐infection care models, early sepsis recognition, and equity‐driven interventions to reduce mortality.

26 August 2025 in The Egyptian Heart Journal
Verified
Journal Article
Open access
PDF file
ARAsad Gul Rao
Asad Gul Rao
APAmna Parvez
Amna Parvez
SSSufyan Shahid
Sufyan Shahid
NPNeha Pervez
Neha Pervez
JRJamal S. Rana
Jamal S. Rana
MKMuhammad Shahzeb Khan
Muhammad Shahzeb Khan
Background: Hypertensive disease and obesity frequently coexist and synergistically increase the risk of cardiovascular morbidity and mortality in the USA. Despite this intersection, national trends and disparities in mortality attributable to both conditions remain underexplored. Methods: We conducted a retrospective analysis using the Centers for Disease Control and Prevention Wide-ranging Online Data for Epidemiologic Research Multiple Cause of Death database. Hypertensive disease-related deaths with co-listed obesity were extracted for US adults between 1999 and 2023. Age-adjusted mortality rates (AAMRs) were calculated, and Joinpoint regression was used to estimate annual percentage changes (APCs) and identify significant trends. Results: A total of 412,767 deaths were attributed to hypertensive disease and coexisting obesity from 1999 and 2023. The AAMRs rose nearly tenfold, from 1.3 per 100,000 in 1999 to 13.23 in 2023. While mortality rates increased overtime for both sexes, men consistently exhibited higher rates than women (AAPC: 10.38 vs. 8.15). Older adults (AAMR: 32.63) had the highest mortality, followed by middle-aged (5.56) and young adults (0.71), though young adults saw the steepest relative rise (AAPC: 9.63). Non-Hispanic (NH) Black individuals had the highest mortality (AAPC: 7.78), followed by NH American Indian/Alaska Native (8.76), NH White (9.90), Hispanic (6.48) and NH Asian/Pacific Islander populations (6.51). Geographic disparities widened over time. The South and Midwest bore the heaviest regional burden, while urban–rural analyses showed a higher and quicker rise in mortality in non-metropolitan areas (AAPC: 12.13 vs. 10.73 in metro areas). Conclusion: Mortality due to hypertensive disease with coexisting obesity has escalated sharply across USA over the past 2 decades. These results highlight the need for further investigation into the factors contributing to the observed disparities and trends. Graphical Mortality due to hypertensive disease and coexisting obesity in the USA: 1999–2023

9 October 2025 in eClinicalMedicine
Verified
Journal Article
Open access
MNMuhammad Ahmad Nadeem
Muhammad Ahmad Nadeem
AAAbdul Rafeh Awan
Abdul Rafeh Awan
ARAsad Gul Rao
Asad Gul Rao
MAMeher Ayyazuddin
Meher Ayyazuddin
UBUmm E. Salma Shabbar Banatwala
Umm E. Salma Shabbar Banatwala
JEJamak Modaresi Esfeh
Jamak Modaresi Esfeh
Endoscopic retrograde cholangiopancreatography (ERCP) is frequently performed in liver transplant recipients for the management of biliary complications. While frequently medically necessary, ERCP carries a risk of post-procedural infections, particularly in immunosuppressed transplant patients. Prophylactic antibiotics are sometimes recommended, but their role remains uncertain. We aimed to address this knowledge gap. This single-arm systematic review and meta-analysis included randomised controlled trials (RCTs), prospective and retrospective cohort studies, and case-control studies evaluating the use of prophylactic antibiotics prior to or during ERCP (for any indication) in liver transplant recipients. No restrictions were placed on patient age, sex, or ethnicity. PubMed, Embase, Cochrane CENTRAL, and Scopus were searched for relevant studies published between database inception and June 2025. Primary outcomes of interest were incidence of post-ERCP cholangitis, infection, or pancreatitis, incidence of overall procedural complications, and mortality attributable to procedural complications. The quality of included studies was assessed via ROBINS-I. This work is registered with PROSPERO, CRD42024604381. This review included 26 studies involving more than 3800 liver transplant recipients undergoing over 7300 ERCP procedures. All studies were non-randomised, comprising nine prospective and 17 retrospective studies. The pooled complication rate was 25.7% per patient and 6.7% per procedure; the pooled cholangitis rate was 8.6% per patient and 3.5% per procedure; and the pooled pancreatitis rate was 6.1% per patient and 1.9% per procedure. In the overall cohort, the pooled mortality rate due to post-ERCP complications was 1.1% with two deaths reported among 594 patients. Both fatalities were attributed to sepsis secondary to cholangitis. Bile cultures were positive in 80.1% of the samples with a sensitivity of 63.7% to prophylactic antibiotics used and 24.3% of isolates resistant to more than one antibiotic. The highest resistance was observed against gentamicin (54.1%) and ceftriaxone (53.7%) while resistance was lower for piperacillin/tazobactam (26.2%) and carbapenems (26.6%). Resistance rates were higher in transplant recipients compared to the general ERCP population. Despite widespread prophylactic antibiotic use, post-ERCP infections and antimicrobial resistance remain prevalent in liver transplant recipients. These findings support more targeted prophylactic strategies using agents with lower resistance rates, particularly in patients undergoing repeat ERCPs. This single-arm analysis did not include a direct comparator group of patients without antibiotic prophylaxis. Future prospective studies and randomised controlled trials are essential to determine the optimal prophylactic regimen, dose, and duration in this high-risk population. None.

1 January 2025 in Anesthesiology Research and Practice
Verified
Journal Article
Open access
MJMohammad Jawwad
Mohammad Jawwad
DDDawar Nadeem Aslam Dar
Dawar Nadeem Aslam Dar
RKRana Faheem Ullah Khan
Rana Faheem Ullah Khan
ACAizaz Chaudhry
Aizaz Chaudhry
FAFaraz Arkam
Faraz Arkam
PPPierina Clementine Pereira
Pierina Clementine Pereira
Background: Pain management is an integral part of recovery after major abdominal surgeries. Traditionally, epidural analgesia is used for postoperative pain management in major abdominal surgeries. However, intravenous lidocaine has recently been proven to be a good alternative. However, there is very limited evidence comparing their efficacy in major abdominal surgery. The aim of this review is to compare the effectiveness of epidural analgesia with intravenous lidocaine in reducing pain and opioid consumption following major abdominal surgery. Methods: We searched PubMed and Cochrane Library from inception to May 2024 to identify studies that match our topic. We performed all statistical analyses using RevMan. The primary outcome was pain scores. The other outcomes were opioid requirements, postoperative nausea and vomiting, hospital stay duration, and time to pass flatus. Results: Seven studies (six randomized clinical trials and one observational study; n = 643) were included. Our results suggest that epidural bupivacaine significantly reduced pain scores during the first 24 h postoperatively as compared with the patients who received intravenous lidocaine (Std. mean difference: −0.23; 95% confidence interval [CI]: −0.40, −0.06; and p = 0.008). There was no difference at 48 h (Std. mean difference: −0.09; 95% CI: −0.27, 0.08; and p = 0.028) and 72 h intervals (Std. mean difference: −0.08; 95% CI: −0.25, 0.09; and p = 0.037). Conclusion: Our study shows that epidural analgesia, particularly epidural bupivacaine, provides superior pain relief as compared to intravenous lidocaine during the first 24 h postoperatively. However, there was heterogeneity among studies. Thus, in future, large standardized randomized controlled trials are required.

16 November 2025 in Journal of Surgical Oncology
Verified
Journal Article
Closed access
ARAsad Gul Rao
Asad Gul Rao
MNMuhammad Ahmad Nadeem
Muhammad Ahmad Nadeem
AAAbdul Rafeh Awan
Abdul Rafeh Awan
CWChase J. Wehrle
Chase J. Wehrle
AGAbby Gross
Abby Gross
RNRob Naples
Rob Naples